- |||||||||| Trial completion, Enrollment change: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=18, Completed, Trial primary completion date: Nov 2015 --> Mar 2016 Recruiting --> Completed | N=30 --> 18
- |||||||||| decitabine / Generic mfg.
Trial primary completion date: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Aug 19, 2014 P2, N=40, Recruiting, Recruiting --> Completed | N=30 --> 18 Trial primary completion date: Dec 2016 --> Dec 2015
- |||||||||| hydroxyurea / Generic mfg.
Trial primary completion date: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Aug 7, 2014 P=N/A, N=60, Recruiting, Trial primary completion date: Dec 2016 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| Trial termination: Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis (clinicaltrials.gov) - Jul 23, 2014
P2, N=18, Terminated, Recruiting --> Active, not recruiting | N=210 --> 110 | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Terminated; 18 or 20 enrolled, stopped due to paucity of available participants
- |||||||||| PF-04447943 / Pfizer
New P1 trial, PK/PD data: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Apr 13, 2014 P1, N=64, Not yet recruiting,
|